Boehringer Ingelheim reported positive Phase 3 findings from the SYNCHRONIZE-1 trial of survodutide (BI 456906), a next-generation injectable that activates both GLP-1 and glucagon receptors. The international study enrolled 725 adults with overweight or obesity (people with type 2 diabetes were excluded) and tested weekly injections over 76 weeks.
Key results
– Mean weight loss on survodutide was 16.6% (about 39.2 pounds) compared with 3.2% for placebo.
– Up to 85.1% of participants on survodutide achieved at least a 5% weight reduction, versus 38.8% with placebo.
– Weekly doses studied were 3.6 mg and 6.0 mg.
– Waist circumference fell significantly, suggesting reductions in visceral fat and potential cardiometabolic benefit.
– Most of the weight lost was fat rather than lean muscle mass.
– Typical GLP-1–class gastrointestinal side effects such as nausea and vomiting were mostly mild to moderate, tended to occur during dose escalation, and were transient. The company said no new safety signals emerged in the announcement.
How survodutide differs from tirzepatide (Mounjaro/Zepbound)
Survodutide combines GLP-1 receptor agonism with glucagon receptor activity, which is a different receptor pairing than tirzepatide’s dual GIP/GLP-1 mechanism. The glucagon component may alter liver metabolism in ways that could reduce liver fat and improve markers of inflammation or fibrosis, so investigators and hepatology specialists are watching for potential benefits for obesity-related liver disease.
Expert perspectives
– Hector Perez, MD, a bariatric surgeon and advisor, described the weight-loss numbers as impressive but urged caution, saying it’s premature to call survodutide a game-changer until full data are available. He highlighted that real-world impact will depend on tolerability and whether patients can remain on treatment. Perez also noted possible value for fatty liver disease due to the glucagon activity.
– Kristin Kuminski, RDN, called the results significant and broadly comparable to tirzepatide, and advised patients to discuss with clinicians how a new drug might stack up on side effects and in people with coexisting conditions.
Practical considerations for patients and clinicians
– Survodutide is not yet approved. Current conversations with clinicians center on pipeline developments and potential trial enrollment.
– Useful topics to discuss with a provider include candidacy for bariatric surgery versus medical therapy, realistic weight-loss expectations, strategies to preserve muscle mass during weight loss, common and expected side effects, what to expect if the medication is stopped, and likely insurance coverage.
– Experts emphasize selecting treatments that match a patient’s body, habits, finances, and ability to sustain long-term therapy rather than focusing solely on headline efficacy numbers.
Bottom line
SYNCHRONIZE-1 results indicate substantial and sustained weight loss and favorable metabolic changes in adults without diabetes, with a tolerability profile consistent with GLP-1–based therapies in the company announcement. Survodutide’s glucagon activity raises particular interest for potential liver benefits, but full trial data and regulatory review are needed before its safety and effectiveness can be fully compared with existing options like tirzepatide/Zepbound.